ATE385575T1 - Versuchsanordnungen, antikörper und standards für den nachweis von oxidierten und mda-modifizierten lipoproteinen geringer dichte - Google Patents

Versuchsanordnungen, antikörper und standards für den nachweis von oxidierten und mda-modifizierten lipoproteinen geringer dichte

Info

Publication number
ATE385575T1
ATE385575T1 AT97930493T AT97930493T ATE385575T1 AT E385575 T1 ATE385575 T1 AT E385575T1 AT 97930493 T AT97930493 T AT 97930493T AT 97930493 T AT97930493 T AT 97930493T AT E385575 T1 ATE385575 T1 AT E385575T1
Authority
AT
Austria
Prior art keywords
mda
low density
oxidized
antibodies
standards
Prior art date
Application number
AT97930493T
Other languages
English (en)
Inventor
Paul Holvoet
Desire Collen
Original Assignee
Leuven Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leuven Res & Dev filed Critical Leuven Res & Dev
Application granted granted Critical
Publication of ATE385575T1 publication Critical patent/ATE385575T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT97930493T 1997-06-20 1997-07-01 Versuchsanordnungen, antikörper und standards für den nachweis von oxidierten und mda-modifizierten lipoproteinen geringer dichte ATE385575T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP9703287 1997-06-20

Publications (1)

Publication Number Publication Date
ATE385575T1 true ATE385575T1 (de) 2008-02-15

Family

ID=8166668

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97930493T ATE385575T1 (de) 1997-06-20 1997-07-01 Versuchsanordnungen, antikörper und standards für den nachweis von oxidierten und mda-modifizierten lipoproteinen geringer dichte

Country Status (9)

Country Link
EP (1) EP1021728B8 (de)
JP (1) JP4233120B2 (de)
AT (1) ATE385575T1 (de)
AU (1) AU3442397A (de)
CA (1) CA2294355C (de)
DE (1) DE69738503T2 (de)
ES (1) ES2299186T3 (de)
NZ (1) NZ502369A (de)
WO (1) WO1998059248A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727102B1 (en) 1997-06-20 2004-04-27 Leuven Research & Development Vzw Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins
US6309888B1 (en) 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
US7250304B2 (en) 2000-03-31 2007-07-31 The Regents Of The University Of California Functional assay of high-density lipoprotein
AU2001249762B2 (en) * 2000-03-31 2006-03-30 The Regents Of The University Of California A functional assay of high-density lipoprotein
US6596544B1 (en) 2000-03-31 2003-07-22 The Regents Of The University Of California Functional assay of high-density lipoprotein
WO2001088547A2 (en) * 2000-05-12 2001-11-22 The Regents Of The University Of California Standardized oxidized ldl assay
GB0017641D0 (en) * 2000-07-18 2000-09-06 Medigene Oy Peptides and their use
AP2034A (en) 2000-10-20 2009-08-28 Hamburger Stiftung Zur Forderung Wissenschaft Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof.
JP4781169B2 (ja) * 2006-05-31 2011-09-28 積水メディカル株式会社 再狭窄の発症リスクを判定する方法
EP4680632A2 (de) 2023-03-17 2026-01-21 Oxitope Pharma B.V. Anti-phosphocholin-antikörper und verfahren zur verwendung davon
CN120741870A (zh) * 2025-09-01 2025-10-03 西安金磁纳米生物技术有限公司 一种基于4e6抗体的氧化型低密度脂蛋白检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3115587B2 (ja) * 1990-11-07 2000-12-11 第一化学薬品株式会社 モノクローナル抗体及びマロンジアルデヒド化低比重リポタンパクの測定法
WO1994023302A1 (en) * 1993-04-07 1994-10-13 The Australian National University Immunological assay of oxidatively modified human low density lipoproteins in plasma

Also Published As

Publication number Publication date
CA2294355C (en) 2006-11-28
NZ502369A (en) 2001-11-30
JP4233120B2 (ja) 2009-03-04
AU3442397A (en) 1999-01-04
CA2294355A1 (en) 1998-12-30
DE69738503T2 (de) 2009-02-26
WO1998059248A1 (en) 1998-12-30
EP1021728B8 (de) 2008-04-23
DE69738503D1 (de) 2008-03-20
EP1021728B1 (de) 2008-02-06
EP1021728A1 (de) 2000-07-26
ES2299186T3 (es) 2008-05-16
JP2002512695A (ja) 2002-04-23

Similar Documents

Publication Publication Date Title
NO976122L (no) AntiFasligandantistoffer og analysefremgangsmåte hvor disse anvendes
ATE385575T1 (de) Versuchsanordnungen, antikörper und standards für den nachweis von oxidierten und mda-modifizierten lipoproteinen geringer dichte
FI962686L (fi) Fluorenssiin perustuva immunomääritysmenetelmä
ATE239228T1 (de) Automatische immunoassay kassette
ATE315228T1 (de) Immunoassay zum bestimmen von bnp
WO2000007025A3 (en) Methods for predicting drug response, in particular igf-i
ATE199263T1 (de) Für den chemilumineszenz-nachweis verwendbare aryl-n-alkylacridanthiocarboxylat-derivate
DE69427123D1 (de) Screeningverfahren für katalytische nicht-enzym-polypeptide und-proteine
WO2003061569A3 (en) High-density lipoprotein assay device and method
DE19781837T1 (de) Automatischer Immunoassay-Analysator
DE69333569D1 (de) Magnetisch assistierte bindungsassays unter verwendung von magnetisch markierten bindungspartnern.
DE3670294D1 (de) Monoklonale antikoerper gegen kernproteine von lymphadenopathie-assoziierten viren.
DE69517693D1 (de) Standardzellenbibliothek für den Entwurf von integrierten Schaltungen
DE59508474D1 (de) RHEUMAFAKTOR-ENTSTÖRUNG MIT ANTI-Fd-ANTIKÖRPERN
DE59805288D1 (de) Immunchemische Bestimmung von multivalenten Analyten
ATE226322T1 (de) Verfahren zum durchführen von bluttests
ATE48037T1 (de) Verfahren und reagenz zur verwendung zur bestimmung von pivka-ii.
ATE18920T1 (de) Radioimmunoassay fuer fibrinopeptid a.
NO970826D0 (no) Analyser for deteksjon av proteaser
IL143057A (en) Method to determine if a compound causes a change in the structure of apolipoprotein b-100 in a cholesterol- containing low-density lipoprotein and increases binding of an epitope on the apolipoprotein b - 100 to the ldl - receptor
DK26587A (da) Monoklonalt antistof, maalemetode for glucosyleret protein ved anvendelse af det monoklonale antistofog kit omfattende dette
DK0974842T3 (da) Reagensmiddel til undersøgelse af virus-agglutination og sæt til virusundersøgelse
ES531436A0 (es) Procedimiento de obtener y aislar hibridomas secretores de anticuerpos, procedimiento de obtener anticuerpos y metodo de obtener polipeptidos
DE69731053D1 (de) Prüfung von Schaltungen mit Schmitt-Eingängen
DE3789087D1 (de) Verfahren zur Bestimmung von Anti-HIV, Mittel dazu und ihre Verwendung in diesem Verfahren.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties